PMID- 36797091
OWN - NLM
STAT- MEDLINE
DCOM- 20230403
LR  - 20230403
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Print)
IS  - 0198-8859 (Linking)
VI  - 84
IP  - 4
DP  - 2023 Apr
TI  - Impact of HLA polymorphisms on the susceptibility to SARS-CoV-2 infection and 
      related mortality in patients with renal replacement therapy.
PG  - 272-277
LID - S0198-8859(23)00023-X [pii]
LID - 10.1016/j.humimm.2023.01.008 [doi]
AB  - Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection could 
      present in a clinical spectrum of varying severity. Human leukocyte antigen (HLA) 
      is a crucial component of the viral antigen presentation pathway and immune 
      response to the virus. Therefore, we aimed to assess the impact of HLA allele 
      polymorphisms on the susceptibility to SARS-CoV-2 infection and related mortality 
      in Turkish kidney transplant recipients and wait listed patients, along with 
      clinical characteristics of the patients. We analysed data from 401 patients with 
      clinical characteristics according to presence (n = 114, COVID+) or absence of 
      SARS-CoV-2 infection (n = 287, COVID-) who had previously been HLA typed to 
      support transplantation. The incidence of coronavirus disease-19 (COVID-19) was 
      28 %, and the mortality rate was 19 % in our wait listed/ transplanted patients. 
      Multivariate logistic regression analysis showed that a significant HLA 
      association between HLA- B*49 (OR = 2.57, 95 % CI, 1.13-5.82; p = 0.02) and HLA- 
      DRB1*14 (OR = 2.48, 95 % CI, 1.18-5.20; p = 0.01) with SARS-CoV-2 infection. 
      Besides, in COVID + patients, HLA-C*03 was correlated to mortality (OR = 8.31, 
      95 % CI, 1.26-54.82; P = 0.03). The new finding from our analysis suggests that 
      HLA polymorphisms could be associated with the occurrence of SARS-CoV-2 infection 
      and COVID-19 mortality in Turkish patients with renal replacement therapy. This 
      study may provide new information for the clinician to identify and manage 
      sub-populations at risk in the setting of the current COVID-19 pandemic.
CI  - Copyright (c) 2023 American Society for Histocompatibility and Immunogenetics. 
      Published by Elsevier Inc. All rights reserved.
FAU - Akcay, Omer Faruk
AU  - Akcay OF
AD  - Gazi University Faculty of Medicine, Department of Nephrology, Ankara, Turkey. 
      Electronic address: omerfaruk_akcay@yahoo.com.
FAU - Yeter, Haci Hasan
AU  - Yeter HH
AD  - Sivas Numune State Hospital, Department of Nephrology, Sivas, Turkey.
FAU - Unsal, Yasemin
AU  - Unsal Y
AD  - Gazi University Faculty of Medicine, Department of Internal Medicine, Ankara, 
      Turkey.
FAU - Yasar, Emre
AU  - Yasar E
AD  - Gazi University Faculty of Medicine, Department of Nephrology, Ankara, Turkey.
FAU - Gonen, Sevim
AU  - Gonen S
AD  - Gazi University Faculty of Medicine, HLA Tissue Typing Laboratory, Ankara, 
      Turkey.
FAU - Derici, Ulver
AU  - Derici U
AD  - Gazi University Faculty of Medicine, Department of Nephrology, Ankara, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20230206
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (HLA-B Antigens)
RN  - 0 (Histocompatibility Antigens Class II)
SB  - IM
MH  - Humans
MH  - *COVID-19/genetics
MH  - SARS-CoV-2
MH  - Pandemics
MH  - Histocompatibility Antigens Class I
MH  - Renal Replacement Therapy
MH  - HLA-B Antigens
MH  - Histocompatibility Antigens Class II
PMC - PMC9899785
OTO - NOTNLM
OT  - COVID-19
OT  - Coronavirus
OT  - Human leukocyte antigen
OT  - Pandemic
OT  - SARS-CoV2
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/02/17 06:00
MHDA- 2023/04/03 06:42
PMCR- 2023/02/06
CRDT- 2023/02/16 22:01
PHST- 2021/12/05 00:00 [received]
PHST- 2023/01/21 00:00 [revised]
PHST- 2023/01/24 00:00 [accepted]
PHST- 2023/04/03 06:42 [medline]
PHST- 2023/02/17 06:00 [pubmed]
PHST- 2023/02/16 22:01 [entrez]
PHST- 2023/02/06 00:00 [pmc-release]
AID - S0198-8859(23)00023-X [pii]
AID - 10.1016/j.humimm.2023.01.008 [doi]
PST - ppublish
SO  - Hum Immunol. 2023 Apr;84(4):272-277. doi: 10.1016/j.humimm.2023.01.008. Epub 2023 
      Feb 6.